SBP 101 - Spark Biopharma
Alternative Names: SB-101; SB101 - Spark Biopharma; SBP101 - Spark BiopharmaLatest Information Update: 13 Sep 2023
At a glance
- Originator Spark BioPharma
- Class Antineoplastics; Small molecules
- Mechanism of Action HMGB protein modulators; HMGB1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Biliary cancer; Glioblastoma; Liver cancer; Skin cancer
Most Recent Events
- 13 Sep 2023 Phase-I clinical trials in Biliary cancer in South Korea (unspecified route) (Spark Biopharma pipeline, September 2023)
- 13 Sep 2023 Phase-I clinical trials in Glioblastoma in South Korea (unspecified route) (Spark Biopharma pipeline, September 2023)
- 13 Sep 2023 Phase-I clinical trials in Liver cancer in South Korea (unspecified route) (Spark Biopharma pipeline, September 2023)